Clinical trials: Alpha-Synucleinopathy
Parkinson's Disease (PD), GBA1 Parkinson Disease
Understanding Alpha-Synuclein Spread in Parkinson's Disease Through Blood Biomarkers and Neuroimaging
The project aims to investigate how abnormal accumulation of alpha synuclein and its interaction with tau influence brain function across the Parkinson's disease (PD) spectrum, with particular focus on individuals carrying GBA1…
- Conditions
- Parkinson's Disease (PD), GBA1 Parkinson Disease, REM Sleep Behavior Disorder (iRBD)
- Trial name
- SYNchronPD (NCT07474779)
- Testing
- brain imaging, blood draw, Skin biopsy
- Where
- 2 sites in Italy
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University of Pavia
Parkinson's Disease
Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain
This is a Phase I clinical trial of the FDA approved drug Glycerol Phenylbutyrate to see if phenylbutyrate can increase the removal of alpha-synuclein from the brain into the bloodstream.
- Trial name
- NCT02046434
- Testing
- Glycerol Phenylbutyrate
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Multiple System Atrophy
Insulin Resistance in Multiple System Atrophy
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder. The pathologic hallmark is the accumulation of aggregated alpha-synuclein in oligodendrocytes forming glial cytoplasmic inclusions.
- Trial name
- IRAMS (NCT04250493)
- Testing
- Homeostasis Model Assessment of insulin resistance (HOMA), MOntreal Cognitive Assessment (MoCA), Clinical characteristics of AMS patients
- Where
- France
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Parkinson's Disease, Multiple System Atrophy
An Observational Study of Parkinson's Disease and Other Synucleinopathies (EASE-PD)
The study is a multi-center, observational study to evaluate the feasibility of α-synuclein-related biomarkers and imaging data in the disease diagnosis and prognosis evaluation in Synucleinopathies and healthy subjects.
- Trial name
- EASE-PD (NCT05638815)
- Where
- 4 sites in China
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- SciNeuro
REM Sleep Behavior Disorder, Neurodegeneration
Progression of Prodromal Markers of α-synucleinopathy Neurodegeneration in the FDRs of Patients With RBD
This study is a prospective study with a mean of 5-year follow-up interval, aims to monitor the progression of α-synucleinopathy neurodegeneration by the evolution of prodromal markers and development of clinical disorders in…
- Trial name
- NCT03671772
- Where
- Hong Kong
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Parkinson Disease
Progression Follow up of the First-degree Relatives of Patients With REM Sleep Behavior Disorder
REM sleep behavior disorder is a novel and distinct parasomnia characterized by recurrent dream enactment behaviors (DEBs) and polysomnographic features of REM sleep without atonia (RSWA), with typical onset age at early 60's.
- Trial name
- NCT05353959
- Testing
- No intervention
- Where
- Hong Kong
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Alzheimer Disease, Frontotemporal Dementia
Proteinopathies Expression in Skin of Neurodegenerative Disorders
The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 [TDP43]) in skin biopsies of…
- Conditions
- Alzheimer Disease, Frontotemporal Dementia, Parkinson Disease, Atypical Parkinsonism
- Trial name
- NCT06528964
- Testing
- Immunohistochemistry and immunofluorescence
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí
Post-operation Delirium, Alpha-synucleinopathy Related Non-motor Symptom
Exploring the Relationship Between Alpha-synucleinopathy Related Non-motor Symptom and Post-op. Delirium in Elderly Patients With Spine Surgery
Hypothesis is that the presence of a-synucleinopathy related non motor symptoms could be predictive factor for post-operative delirium.
- Trial name
- NCT02550626
- Where
- South Korea
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Parkinson Disease
Effect of WB-EMS on Parkinson's Disease
The aim is to establish adequate and suitable protocols for PD patients and to determine the WB-EMS effects on muscle strength, balance, walking, cognitive functions,neurotrophic factors and alpha-synuclein.
- Trial name
- NCT04878679
- Testing
- Strenght training combined with WB-EMS, Cardiovascular training with WB-EMS, Control group
- Where
- Italy
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Università degli studi di Roma Foro Italico
Healthy Volunteers
A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)
The purpose of this healthy volunteers drug-drug interaction study is to assess the CYP1A2 and CYP3A4 perpetrator interaction potential and CYP1A2 victim potential of TEV-56286 (anle138b).
- Trial name
- NCT05532358
- Testing
- anle138b (TEV-56286), Fluvoxamine 100 mg QD for 5 days
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Multiple System Atrophy, Parkinson's Disease
Prospective Multicenter Registry Study of Multiple System Atrophy in China
Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease characterized by variable combinations of parkinsonism, cerebellar ataxia, and autonomic dysfunction.
- Conditions
- Multiple System Atrophy, Parkinson's Disease, Atypical Parkinsonism
- Trial name
- MSA Registry S (NCT07644013)
- Where
- China
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Parkinson Disease, Multiple System Atrophy
A Pilot Biomarker Study Assessing Alpha-synuclein Aggregates Across Biofluid Reservoirs in Patients With Synucleinopathies
This will be an observational study looking at clinical and biomarker characteristics in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Rapid Eye Movement Sleep Behavior Disorder (RBD), Normal Pressure…
- Conditions
- Parkinson Disease, Multiple System Atrophy, Rapid Eye Movement Sleep Behavior Disorder, Normal Pressure Hydrocephalus
- Trial name
- NCT04020198
- Testing
- Biomarker assay
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Stony Brook University
Lewy Body Disease
Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease
The goal of the study is to assess if learning one's Lewy Body Dementia (LBD) biomarker test result impacts longitudinal psychosocial and behavioral responses and to identify factors that moderate and mediate these outcomes.
- Trial name
- NCT07646652
- Testing
- LBD Biomarker Education and Disclosure
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Stanford University
Healthy Volunteers
A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b in healthy subjects.
- Trial name
- NCT04208152
- Testing
- anle138b
- Where
- United Kingdom
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Parkinson Disease, Irritable Bowel Syndrome
Early Signs of Parkinsons Disease in IBS
Bowel symptoms like constipation and abdominal pain are characteristic symptoms of irritable bowel syndrome (IBS). The pathogenesis and pathophysiology are not fully understood but subject to intense research, with emphasis on…
- Trial name
- NCT05573542
- Where
- Sweden
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Örebro University, Sweden
REM Sleep Behavior Disorder
Prodromal Markers in Recurrent Dream Enactment Behaviors Without REM Sleep Without Atonia
REM sleep behavior disorder is a novel and distinct parasomnia characterized by recurrent dream enactment behaviors (DEBs) and REM sleep without atonia (RSWA) during polysomnographic assessment, with a male predominance and…
- Trial name
- NCT05353881
- Testing
- No intervention
- Where
- Hong Kong
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Parkinson's Disease
Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease
In Parkinson's disease (PD), alpha-synuclein accumulation in cutaneous autonomic pilomotor and sudomotor nerve fibers has been linked to autonomic nervous system disturbances even in the early stages of the disease.
- Trial name
- CAPTURE-PD (NCT03043768)
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GWT-TUD GmbH
REM Sleep Behavior Disorder, Synucleinopathies
A Comprehensive, Multimodal Characterization of Prodromal PD in Subjects With RBD
Comprehensive characterization of early-stage Parkinson's disease in patients with REM sleep behavior disorder Parkinson's disease (PD) is the fastest-growing neurodegenerative disorder worldwide, significantly affecting quality…
- Conditions
- REM Sleep Behavior Disorder, Synucleinopathies, Parkinson's Disease (PD), Prodromal Parkinson's Disease
- Trial name
- 7T-RBD (NCT07790744)
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Danish Research Centre for Magnetic Resonance
Parkinson Disease, Synucleinopathy
Toward Molecular Profiling of Parkinson's Disease in Easily Accessible Biological Matrices
Parkinson's disease (PD) is a synucleinopathy and the most common neurodegenerative disease involving disabling motor deficits. PD is clinically heterogeneous; motor symptoms may be accompanied by nonmotor symptoms such as…
- Conditions
- Parkinson Disease, Synucleinopathy, Alzheimer Disease
- Trial name
- NCT07480187
- Testing
- biomarkers
- Where
- 3 sites in Italy
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera di Perugia
Parkinson Disease, Parkinsonian Disorders
Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.
Parkinson's disease (PD) is a degenerative disease that can be difficult to diagnose. The clinicopathological studies had demonstrated a 76% accuracy in the clinical diagnosis of PD.
- Trial name
- NCT01380899
- Testing
- Biopsy of skin
- Where
- Mexico
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí